Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Journal
Lancet (London, England)
Journal Volume
402
Journal Issue
10408
Date Issued
2023-09-30
Author(s)
Qin, Shukui
Chan, Stephen L
Gu, Shanzhi
Bai, Yuxian
Ren, Zhenggang
Lin, Xiaoyan
Chen, Zhendong
Jia, Weidong
Jin, Yongdong
Guo, Yabing
Hu, Xiaohua
Meng, Zhiqiang
Liang, Jun
Cheng, Ying
Xiong, Jianping
Ren, Hong
Yang, Fang
Li, Wei
Chen, Yajin
Zeng, Yong
Sultanbaev, Alexander
Pazgan-Simon, Monika
Pisetska, Margaryta
Melisi, Davide
Ponomarenko, Dmitriy
Osypchuk, Yurii
Sinielnikov, Ivan
Yang, Tsai-Sheng
Liang, Xiao
Chen, Chunxia
Wang, Linna
Kaseb, Ahmed
Vogel, Arndt
Abstract
Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not in hepatocellular carcinoma. Therefore, a clinical study was conducted to compare the efficacy and safety of the anti-PD-1 antibody camrelizumab plus the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
SDGs
Type
journal article